IMG-007 is now known as Olevaprubart!

Designed to be different:

Developing a potential best-in-class anti-OX40 treatment with features that matter to patients

ImageneBio is a clinical-stage biotechnology company developing therapeutics for patients who have immunological, autoimmune and inflammatory diseases. Olevaprubart is our next-generation investigational anti-OX40 monoclonal antibody.

background patient image
background patient image

Olevaprubart

Olevaprubart is an extended half-life anti-OX40 monoclonal antibody in clinical development that targets and inhibits OX40 receptor signaling without depleting T cells for potential enhanced efficacy, safety, and patient convenience.

News

August 05, 2026

ImageneBio Reports Second Quarter 2026 Financial Results

read more »

July 07, 2026

ImageneBio Appoints Matt Robbins as General Counsel

read more »

May 27, 2026

ImageneBio to Participate in 2026 Jefferies Global Healthcare Conference in New York

read more »
Scroll to Top
Secret Link